8-K · BMY

Bristol Myers Squibb files an 8-K on quarterly results and investor materials (Reg FD)

Filed with the SEC Oct 29, 2026, 7:05 AM ET · Posted Oct 29, 2026, 8:25 AM ET

Bristol Myers Squibb filed a Form 8-K on Oct 29, 2026 at 7:05 AM ET under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure).

Under Item 2.02, the filing says: “On October 29, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the third quarter of 2026.”

Under Item 7.01, the filing says: “On October 29, 2026, the Company posted on its website at www.bms.com a presentation (the “Bristol Myers Presentation”) on certain financial and operating initiatives available for viewing during the Company’s conference call and webcast announcing its financial results for the third quarter of 2026 at 8:00 a.m.”

The filing attaches a press release as Exhibit 99.1 (PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED OCTOBER 29, 2026).

Source

8-K filed Oct 29, 2026 (document)
Filing index on SEC EDGAR (all documents and exhibits)

Bristol Myers Squibb company file → · More Bristol Myers Squibb filings

Disclosures

Editor holdings in BMY: The editor holds no position in Bristol Myers Squibb (BMY). As of Oct 25, 2026.
Last updated: Oct 29, 2026

A summary of a public filing for general education, the same for every reader. Not a recommendation to buy, sell or hold BMY.